U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Cervical Neuroendocrine Tumor G1

MedGen UID:
927348
•Concept ID:
C4289816
•
Neoplastic Process
Synonym: Cervical Low Grade Neuroendocrine Tumor, Grade 1

Definition

A well-differentiated, low grade neuroendocrine neoplasm that arises from the cervix. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVCervical Neuroendocrine Tumor G1

Professional guidelines

PubMed

Radio hyperthermia for re-treatment of superficial tumours.
Gabriele P, Ferrara T, Baiotto B, Garibaldi E, Marini PG, Penduzzu G, Giovannini V, Bardati F, Guiot C
Int J Hyperthermia 2009 May;25(3):189-98. doi: 10.1080/02656730802669593. PMID: 19212860

Recent clinical studies

Etiology

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours.
Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumarianou A, van Dijkum EN, O'Toole D, Rindi G, Scoazec JY, Ramage J
J Neuroendocrinol 2023 Jun;35(6):e13309. Epub 2023 Jun 22 doi: 10.1111/jne.13309. PMID: 37345509
Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A, Faron M, Fodil-Cherif S, Bayle A, Lamartina L, Planchard D, Tselikas L, Kanaan C, Scoazec JY, Ducreux M, Italiano A, Baudin E, Hadoux J
Eur J Cancer 2023 Jun;186:122-132. Epub 2023 Mar 24 doi: 10.1016/j.ejca.2023.03.024. PMID: 37062210
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB
J Immunother Cancer 2022 Oct;10(10) doi: 10.1136/jitc-2022-005471. PMID: 36302562Free PMC Article
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS
Lancet 2022 Sep 24;400(10357):1008-1019. Epub 2022 Sep 12 doi: 10.1016/S0140-6736(22)01659-2. PMID: 36108657Free PMC Article
Neoadjuvant immunotherapy of locoregionally advanced solid tumors.
Tarhini AA, Eads JR, Moore KN, Tatard-Leitman V, Wright J, Forde PM, Ferris RL
J Immunother Cancer 2022 Aug;10(8) doi: 10.1136/jitc-2022-005036. PMID: 35973745Free PMC Article

Diagnosis

World premiere: transoral robot-assisted excision for nasopharyngeal ectopic pituitary adenoma.
Louerat S, Hans S, Laroche S, Hyvrard C, Baudouin R
Eur Arch Otorhinolaryngol 2024 Dec;281(12):6705-6709. Epub 2024 Jul 31 doi: 10.1007/s00405-024-08850-3. PMID: 39083058
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours.
Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumarianou A, van Dijkum EN, O'Toole D, Rindi G, Scoazec JY, Ramage J
J Neuroendocrinol 2023 Jun;35(6):e13309. Epub 2023 Jun 22 doi: 10.1111/jne.13309. PMID: 37345509
Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.
Mete O, Wenig BM
Head Neck Pathol 2022 Mar;16(1):123-142. Epub 2022 Mar 21 doi: 10.1007/s12105-022-01435-8. PMID: 35312985Free PMC Article
CDK4 and TERT amplification in head and neck mucosal melanoma.
Lyu J, Miao Y, Yu F, Chang C, Guo W, Zhu H
J Oral Pathol Med 2021 Nov;50(10):971-978. Epub 2021 Apr 12 doi: 10.1111/jop.13180. PMID: 33797827
Immunohistochemical expression of p16, p21, p27 and cyclin D1 in oral nevi and melanoma.
de Andrade BA, León JE, Carlos R, Delgado-Azañero W, Mosqueda-Taylor A, de Almeida OP
Head Neck Pathol 2012 Sep;6(3):297-304. Epub 2012 Feb 5 doi: 10.1007/s12105-012-0334-y. PMID: 22311377Free PMC Article

Therapy

Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.
Mooradian MJ, Fintelmann FJ, LaSalle TJ, Simon J, Graur A, Muzikansky A, Mino-Kenudson M, Shalhout S, Kaufman HL, Jenkins RW, Lawrence D, Lawless A, Sharova T, Uppot RN, Fang J, Blaum EM, Gonye ALK, Gushterova I, Boland GM, Azzoli C, Hacohen N, Sade-Feldman M, Sullivan RJ
Nat Commun 2024 Aug 27;15(1):7357. doi: 10.1038/s41467-024-51722-x. PMID: 39191779Free PMC Article
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Khushalani NI, Ott PA, Ferris RL, Cascone T, Schadendorf D, Le DT, Sharma MR, Barlesi F, Sharfman W, Luke JJ, Melero I, Lathers D, Neely J, Suryawanshi S, Sanyal A, Holloway JL, Suryawanshi R, Ely S, Segal NH
J Immunother Cancer 2024 Mar 7;12(3) doi: 10.1136/jitc-2023-007364. PMID: 38458639Free PMC Article
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, Gayevskiy V, Elhossiny AM, Srivastava MK, Patil NS, Smith KA, Jesudason R, Chan C, Chang PS, Fernandez M, Rost S, McGinnis LM, Koeppen H, Gay CM, Minna JD, Heymach JV, Chan JM, Rudin CM, Byers LA, Liu SV, Reck M, Shames DS
Cancer Cell 2024 Mar 11;42(3):429-443.e4. Epub 2024 Feb 15 doi: 10.1016/j.ccell.2024.01.010. PMID: 38366589
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB
J Immunother Cancer 2022 Oct;10(10) doi: 10.1136/jitc-2022-005471. PMID: 36302562Free PMC Article
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS
Lancet 2022 Sep 24;400(10357):1008-1019. Epub 2022 Sep 12 doi: 10.1016/S0140-6736(22)01659-2. PMID: 36108657Free PMC Article

Prognosis

Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A, Faron M, Fodil-Cherif S, Bayle A, Lamartina L, Planchard D, Tselikas L, Kanaan C, Scoazec JY, Ducreux M, Italiano A, Baudin E, Hadoux J
Eur J Cancer 2023 Jun;186:122-132. Epub 2023 Mar 24 doi: 10.1016/j.ejca.2023.03.024. PMID: 37062210
Persistent mutation burden drives sustained anti-tumor immune responses.
Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V
Nat Med 2023 Feb;29(2):440-449. Epub 2023 Jan 26 doi: 10.1038/s41591-022-02163-w. PMID: 36702947Free PMC Article
"Neuroendocrine Tumor Grade 3 (NET G3)" of the Uterine Cervix: A Report of 2 Cases.
Katafuchi T, Kawakami F, Iwagoi Y, Saito F, Mikami Y
Int J Gynecol Pathol 2022 Sep 1;41(5):470-475. Epub 2021 Sep 27 doi: 10.1097/PGP.0000000000000828. PMID: 34570015
Clear cell neuroendocrine tumor in the gallbladder diagnosed as a benign polyp preoperatively: a case report.
Sumiya R, Shimizu A, Nagai T, Ono H, Kumazawa K, Endo D, Oide T, Aoyanagi N
World J Surg Oncol 2021 Jan 2;19(1):3. doi: 10.1186/s12957-020-02104-2. PMID: 33388069Free PMC Article
Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study.
Zhu LM, Tang L, Qiao XW, Wolin E, Nissen NN, Dhall D, Chen J, Shen L, Chi Y, Yuan YZ, Ben QW, Lv B, Zhou YR, Bai CM, Chen J, Song YL, Song TT, Lu CM, Yu R, Chen YJ
Medicine (Baltimore) 2016 Feb;95(7):e2836. doi: 10.1097/MD.0000000000002836. PMID: 26886644Free PMC Article

Clinical prediction guides

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Khushalani NI, Ott PA, Ferris RL, Cascone T, Schadendorf D, Le DT, Sharma MR, Barlesi F, Sharfman W, Luke JJ, Melero I, Lathers D, Neely J, Suryawanshi S, Sanyal A, Holloway JL, Suryawanshi R, Ely S, Segal NH
J Immunother Cancer 2024 Mar 7;12(3) doi: 10.1136/jitc-2023-007364. PMID: 38458639Free PMC Article
Persistent mutation burden drives sustained anti-tumor immune responses.
Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V
Nat Med 2023 Feb;29(2):440-449. Epub 2023 Jan 26 doi: 10.1038/s41591-022-02163-w. PMID: 36702947Free PMC Article
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS
Lancet 2022 Sep 24;400(10357):1008-1019. Epub 2022 Sep 12 doi: 10.1016/S0140-6736(22)01659-2. PMID: 36108657Free PMC Article
P14ARF deficiency and its correlation with overexpression of p53/MDM2 in sporadic vestibular schwannomas.
Chen Y, Wang ZY, Wu H
Eur Arch Otorhinolaryngol 2015 Sep;272(9):2227-34. Epub 2014 Jun 26 doi: 10.1007/s00405-014-3135-y. PMID: 24964769
Involvement of p21 (waf1) in merlin deficient sporadic vestibular schwannomas.
Wu H, Chen Y, Wang ZY, Li W, Li JQ, Zhang L, Lu YJ
Neuroscience 2010 Sep 29;170(1):149-55. Epub 2010 Jul 1 doi: 10.1016/j.neuroscience.2010.06.051. PMID: 20600642

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...